The software has two components, one pertaining to the provision of citrate anticoagulation and the other allowing for use of the Gambro MARS liver support therapy in conjunction with the Prismaflex system.
Effective CRRT dose delivery is largely predicated upon adequate anticoagulation of the extracorporeal circuit, according to Gambro. However, a significant proportion of critically ill AKI patients are at high risk of bleeding and systemic anticoagulation with heparin is not feasible.
Although citrate anticoagulation is a very good alternative in such patients, its efficacy relies on removal of calcium from the blood before it enters the CRRT filter, according to Gambro. Therefore, to maintain normal calcium levels, reinfusion of calcium into the blood after the CRRT filter is required. With the Prismaflex eXeed II software, this calcium substitution is fully integrated and controlled by the Prismaflex system in accordance with other CRRT prescription parameters.
In addition to integrated calcium management during the course of citrate anticoagulation, the Prismaflex eXeed II software now provides clinicians the opportunity to prescribe the Molecular Adsorbent Recirculating System (MARS) through a dedicated Prismaflex user interface.
The user interface displays on-line instructions to guide the user through therapy setup and to simplify therapy implementation. In this manner, the Prismaflex system becomes a part of the delivery of MARS therapy to patients with a variety of liver disorders.
The Prismaflex eXeed II system will be available in most European countries, Australia/ New Zealand and various Asian countries. It will be gradually introduced globally.